UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
XENE
Xenon Pharmaceuticals Inc.
There isn't enough reported data to score XENE yet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
XENE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
XENE's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
XENE PE Valuation
XENE has no meaningful PE right now: it lost money over the past year.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
XENE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect XENE's revenue to grow, with its earnings and profitability holding steady.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over XENE on earnings quality, reporting a profit while its opponent remains loss making.
XENE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.70 | -$0.82 |
| Q2 2026 | -$4.74 | -$1.20 |
| Q1 2026 | -$4.70 | -$1.48 |
| Q4 2025 | -$4.36 | -$1.35 |
| Q3 2025 | -$3.88 | -$1.05 |
| Q2 2025 | -$3.54 | -$0.79 |
| Q1 2025 | -$3.22 | -$0.50 |
| Q4 2024 | -$3.01 | -$0.28 |
XENE lost $4.70 per share over the past year, a bigger loss than the year before.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over XENE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
XENE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $132K | -98% |
| Q2 2022 | $536K | -76% |
| Q1 2022 | $8.8M | +101% |
| Q4 2021 | $3.7M | -27% |
| Q3 2021 | $8.1M | +24% |
| Q2 2021 | $2.2M | -83% |
| Q1 2021 | $4.4M | -38% |
| Q4 2020 | $5.2M | +55% |
XENE's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -970% | N/A |
| Q3 2022 | -28885% | -28693 points |
| Q2 2022 | -5656% | -4641 points |
| Q1 2022 | -198% | +170 points |
| Q4 2021 | -665% | -414 points |
| Q3 2021 | -192% | -44 points |
| Q2 2021 | -1014% | -1010 points |
| Q1 2021 | -368% | -255 points |
XENE's operating margin was −970% last quarter, down 305 points from the same quarter a year ago.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over XENE on cash generation, producing positive trailing cash flow while its opponent burns cash.
XENE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$90.6M | -$18.6M |
| Q2 2026 | -$95.7M | -$31.3M |
| Q1 2026 | -$89M | -$27.3M |
| Q4 2025 | -$81.8M | -$26.6M |
| Q3 2025 | -$72M | -$20.3M |
| Q2 2025 | -$64.4M | -$30.2M |
| Q1 2025 | -$61.7M | -$18.3M |
| Q4 2024 | -$55.2M | -$19.6M |
XENE has burned cash in almost every quarter: −$357M over the past year, against −$253M the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over XENE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
XENE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +156K shares |
| 1 year | +26% | +20.5M shares |
| 3 years | +51% | +33.8M shares |
| 5 years | +142% | +58.6M shares |
| Available history | +201% | +66.6M shares |
XENE has 100M diluted shares, up 26% from a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
XENE Net Leverage
XENE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
XENE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 17.7 | Oversold |
XENE's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
XENE PE vs Healthcare Sector
XENE has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over XENE on trend strength, trading above more of its moving averages.
XENE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $37.2 | 10% above |
| 20 week MA | $51.4 | 20% below |
| 50 week MA | $50.3 | 18% below |
| 100 week MA | $43.4 | 5.4% below |
| 200 week MA | $41.5 | 1.3% below |
XENE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 1.3% below its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over XENE on returns for 2026, with the stronger performance.
XENE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.4 | $15.3 | +14% |
| 2021 | $15.3 | $30.5 | +100% |
| 2022 | $30.5 | $38.1 | +25% |
| 2023 | $38.1 | $46.1 | +21% |
| 2024 | $46.1 | $38.8 | -16% |
| 2025 | $38.8 | $44.8 | +15% |
| 2026 YTD | $44.8 | $41.0 | -8.6% |
XENE has finished higher in five of the last six years. It's down 8.6% so far in 2026.